Table 1.
Patient characteristics and outcomes in the discovery (n = 110) and validation (n = 94) cohorts: discovery cohort
| 1-y overall survival | 1-y relapse rate | ||||
|---|---|---|---|---|---|
| n | Probability (%) | HR (95%CI) (risk of death) | Cumulative incidence (%) | HR (95%CI) (risk of relapse) | |
| Age* | P = .08 | P = .74 | |||
| ≤40 y | 59 | 52.4 | 1 | 32.7 | 1 |
| >40 y | 51 | 35.6 | 1.57 (0.94-2.63) | 36.0 | 1.12 (0.56-2.22) |
| Sex | P = .23 | P = .24 | |||
| Male | 48 | 40.6 | 1 | 40.5 | 1 |
| Female | 62 | 47.9 | 0.73 (0.44-1.22) | 35.1 | 0.66 (0.23-1.61) |
| Diagnosis | P = .75 | P = .40 | |||
| AML | 44 | 41.5 | 1 | 41.0 | 1 |
| Acute lymphoblastic leukemia | 24 | 41.7 | 0.95 (0.49-1.84) | 23.1 | 0.51 (0.18-1.38) |
| Myelodysplastic syndromes | 19 | 40.6 | 1.00 (0.49-2.0) | 47.6 | 1.06 (0.45-2.48) |
| Lymphoproliferative disorder†I | 22 | 43.3 | 0.75 (0.28-1.51) | 30.3 | 0.44 (0.13-1.50) |
| Chronic myeloid leukemia | 1 | 100.0 | — | 0.0 | — |
| Disease status at transplant | P = .06 | P = .006 | |||
| Complete remission | 67 | 52.9 | 1 | 23.2 | 1 |
| Refractory/relapsed disease | 43 | 31.9 | 1.63 (0.97-2.73) | 51.3 | 2.55 (1.27-5.10) |
| Conditioning regimen | P = .20 | P = .55 | |||
| Myeloablative | 79 | 38.1 | 1 | 46.3 | 1 |
| Nonmyeloablative | 31 | 22.1 | 1.19 (0.67-2.09) | 40.9 | 0.56 (0.23-1.36) |
| Graft | P = .22 | P = .20 | |||
| Double cord | 105 | 45.9 | 1 | 32.6 | 1 |
| Single cord | 5 | 20.0 | 1.36 (0.82-2.27) | 0.60 | 1.51 (0.84-2.74) |
| CMV status‡ | P = .84 | P = .43 | |||
| Seronegative | 11 | 53.0 | 1 | 56.2 | 1 |
| Seropositive | 97 | 43.6 | 1.10 (0.44-2.75) | 32.0 | 0.66 (0.23-1.89) |
| HLA match between recipient and dominant CB unit§ | P = .50 | P = .34 | |||
| 7-8/8 | 16 | 61.4 | 1 | 25.1 | 1 |
| 5-6/8 | 46 | 47.1 | 1.41 (0.48-4.13) | 30.1 | 1.33 (0.42-6.01) |
| ≤4/8 | 38 | 40.8 | 1.80 (0.61-5.27) | 39.6 | 1.60 (0.61-4.81) |
| Total mononuclear cells infused|| | P = .90 | P = .99 | |||
| ≤4.1 × 108/kg | 56 | 46.1 | 1 | 34.2 | 1 |
| >4.1 × 108/kg | 54 | 42.6 | 1.035 (0.62-1.73) | 33.5 | 0.99 (0.50-1.96) |
| Patient HLA C group | P < .001 | P < .001 | |||
| C1/C1 | 31 | 59.9 | 1 | 27.3 | 1 |
| C1/C2 | 55 | 48.7 | 1.35 (0.68-2.67) | 24.9 | 0.92 (0.38-2.26) |
| C2/C2 | 24 | 15.0 | 4.33 (2.10-8.94) | 67.8 | 4.05 (1.66-9.87) |
| Patient HLA C group | P < .001 | P < .001 | |||
| C1/x | 86 | 52.9 | 1 | 26.0 | 1 |
| C2/C2 | 24 | 15.0 | 3.56 (2.05-6.18) | 67.8 | 4.25 (2.09-8.63) |
| Patients receiving CB grafts with the combined HLA-C1-KIR2DL2/L3/S2 genotype¶ | P = .002 | P = .009 | |||
| Yes | 67 | 64.6 | 1 | 46.9 | 1 |
| No | 37 | 34.3 | 2.65 (1.39-5.03) | 16.0 | 3.07 (1.26-7.47) |
| HLA-C1/x patients receiving CB grafts with the combined HLA-C1-KIR2DL2/L3/S2 genotype¶ | P = .003 | P = .002 | |||
| Yes | 31 | 74.2 | 1 | 6.7 | 1 |
| No | 49 | 41.3 | 3.31 (1.45-7.50) | 40.1 | 6.98 (1.61-30.25) |
| Patients receiving CB grafts with the combined HLA-C2-KIR2DL1/S1 genotype¶ | P = .17 | P = .72 | |||
| Yes | 47 | 51.9 | 1 | 35.2 | 1 |
| No | 57 | 39.1 | 1.45 (0.85-2.49) | 34.0 | 1.13 (0.56-2.27) |
| Number of CB units with haplotype B¶ | P = .45 | P = .30 | |||
| 2 CB units | 88 | 44.9 | 1 | 31.2 | 1 |
| 1 CB units | 14 | 42.9 | 0.961 (0.45-2.03) | 43.6 | 1.37 (0.18-10.15) |
| 0 CB units | 2 | 50.0 | 1.12 (0.09-16.27) | 50.0 | 2.12 (0.91-4.93) |
*
The median age was 38 y (range, 2-73).
†
Six patients had Hodgkin disease; 4 had chronic lymphocytic leukemia, and 12 had non-Hodgkin lymphoma.
‡
Two patients had missing data.
§
The identity of the dominant CB unit could not be ascertained in 14 cases.
||
The median value for the total nucleated cells infused was 4.1 × 108/kg (range, 2.0 × 108/kg to 19.5 × 108/kg).
¶
Six patients had missing data.